Soluble Fas is increased in serum of patients with primary biliary cirrhosis, but is not a useful marker for disease activity [20]

American Journal of Gastroenterology

Volumn 95, Issue 11, 2000, Pages 3328-3329

  Gozlan, Joël ^a   Nion, Isabelle ^a   Chazouillères, Olivier ^a   Chrétien, Yves ^a   Poupon, Raoul ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; URSODEOXYCHOLIC ACID;

ADULT; APOPTOSIS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; HEPATITIS C; HUMAN; LETTER; LIVER CIRRHOSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

EID: 0033766113     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02120-1     Document Type: Letter

References (7)

1. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis
2. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis
3. Fas ligand - Caught between Scylla and Charybdis
4. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation
5. Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease
6. Soluble Fas (Apo-1, CD 95) and soluble Fas ligand in rheumatic diseases
7. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas